INTRODUCTION

1
Enhancers are traditionally defined as genomic sequences that regulate the transcription of one or more genes, regardless 2 of orientation or relative distance to the target promoter 1 . These cis-regulatory regions can bind specific transcription 3 factors and cofactors to increase transcription, and in current models of enhancer function, they physically interact with 4 their long-range targets via loops in the three-dimensional chromatin structure [1] [2] [3] . Enhancers play a vital role in the 5 regulation of genes during development and cell differentiation 3, 4 . Genetic variation in enhancers has been implicated in 6 etiology of complex disease 5, 6 and in differences between closely related species 7-9 .
7
Given their importance, enhancers have seen considerable study in recent years. More than 2,300 papers have 8 been published on enhancer biology (MeSH: Enhancer Elements, Genetic) since the start of 2015, and hundreds of these 9 have focused on the role of enhancers in disease. Despite the importance of enhancers, they remain difficult to 10 identify 1, 10, 11 . Experimental assays that directly confirm enhancer activity are time-consuming, expensive, and not always 11 conclusive 1, 12 . And, despite recent promising developments in massively parallel reporter assays, current methods are 12 unable to definitively identify and test enhancers on an unbiased genome-wide scale 13 . As a result, many studies have used 13 more easily measurable attributes associated with enhancer activity, including DNA sequence motifs, evolutionary 14 conservation, and biochemical properties, as proxies for enhancer activity 1, [14] [15] [16] [17] 
38
We evaluated the robustness of this "single definition" approach by performing a comprehensive analysis of 39 similarities in genomic, evolutionary, and functional attributes of enhancers identified by different strategies in two tissues
40
(liver and heart) and two cell lines (K562 and Gm12878). By comparing characteristics of different enhancer sets 41 identified in the same biological context, we were able to assess the stability of conclusions made using only one enhancer 42 identification strategy. While we expected some variation due to differences in the underlying assays, we found 43 significant differences between enhancer sets identified in the same context. These differences between identification 
20
"H3K27ac" set includes all H3K27ac ChIP-seq peaks without additional refinement [58] [59] [60] [61] [62] . The "H3K27acPlusH3K4me1"
21
set includes all H3K27ac ChIP-seq peaks that also overlap an H3K4me1 peak, and the "H3K27acMinusH3K4me3" set 22
contains H3K27ac peaks that do not overlap an H3K4me3 peak 38, 39, 63 . In liver only, we have an additional set of enhancers 23
identified from H3K27ac ChIP-seq peaks without overlapping H3K4me3 peaks for comparison ("Villar15") 38 . We also 24 considered a method that incorporates DNase I hypersensitive sites (DHSs) with histone modifications to generate the 25 "DNasePlusHistone" enhancer set, which is composed of DHSs where the ratio of H3K4me1 to H3K4me3 is less than 26 one 40 . Since transcriptional signatures are increasingly used to identify enhancers, we consider "FANTOM" enhancers 27 identified from bidirectionally transcribed eRNA detected via cap analysis of gene expression (CAGE) by the FANTOM5
28
Project 26,64,65 . We also include several methods that combine machine learning with functional genomics data, such as the 29 ENCODE consortium's "EncodeEnhancerlike" made by combining DHSs and H3K27ac peaks using an unsupervised 30 ranking method and the "ChromHMM" predictions generated by a hidden Markov model trained on ChIP-seq data from 31 eight histone modifications, CTCF, and RNA Pol II 15, [66] [67] [68] . For the K562 and Gm12878 cell lines we also include enhancer 32 predictions made by two supervised machine learning methods trained to identify enhancers based on ChIP-seq data in 33 conjunction with other functional genomic features. We will refer to these sets as "Yip12" and "Ho14" 36, 37 . An overview 34 of the data and computational approaches used by each method is given in Figure 1 Figure 2 ; Figure S1 ). Different identification methods assay different 41 aspects of enhancer biology (e.g., co-factor binding, histone modification, enhancer RNAs), and therefore we expected to 42 find variation among enhancer sets. Nevertheless, the magnitude of differences we observed is striking. For each attribute
43
we considered, enhancer sets differ by several orders of magnitude (Table 1 ; Figure 2 features, such as transcription start sites (TSSs). For example, in liver, the average distance to the nearest TSS ranges from 1 14 kb for EncodeEnhancerlike to 64 kb for DNasePlusHistone (Table S1 ). Overall, methods based on histone 2 modifications tend to identify larger numbers of longer enhancers compared with CAGE data, and machine learning 3 methods are variable. We highlight these trends in liver, but they are similar in other contexts (Table 1 ; Figure 2 ; Figure   4 S1).
6
Enhancer sets overlap more than expected by chance, but have low genomic similarity: Given the diversity of the 7 enhancer sets identified by different methods, we evaluated the extent of bp overlap between them. All pairs of enhancer 8 sets overlap more than one could expect if they were randomly distributed across the genome ( Figure 3A ,B, p < 0.001 for 9 all pairs). As expected due to the greater cellular heterogeneity and genetic variation of tissue samples vs. cell lines, 10 enhancer sets identified by different methods in the same cell line have more significant overlap than enhancer sets 11 identified in tissues ( Figure 3B ). However, the magnitude of overlap between enhancer sets is typically low: less than 12 50% for nearly all pairs of methods (median 20% bp overlap for K562 and 31% for liver; Figure 3C ,D, Figure S2A ,B;
13 Figure 3E ,F, Figure S2C ,D, upper triangle). Since the Jaccard similarity is sensitive to differences in set size, we 21 also computed a "relative" Jaccard similarity by dividing the observed value by the maximum value possible given the set 22 sizes. The relative similarities were also consistently low ( Figure 3E ,F, Figure S2C ,D, lower triangle).
23
To assess the influence of technical variation on the observed overlaps, we compared the overlap of replicates 24 from H3K27ac ChIP-seq data in the K562 and Gm12878 cell lines generated by the same laboratory. We expected the 25 replicates to have high overlap and serve as an "upper bound" on similarity in practical applications. (Table S5) . As in the full GWAS set, the majority of curated GWAS
45
liver SNPs with any enhancer overlap are overlapped by a single method (53%) and none are shared by all methods
46
( Figure 4C ). The heart and liver enhancer sets are almost universally more enriched for overlap with GWAS SNPs that influence relevant phenotypes compared to GWAS SNPs overall ( Figure 4D ; Table S7 ). Across liver enhancer sets, 50% (33,941 / 68,563) of all overlapped eQTL 7 are called an enhancer by only a single method ( Figure 4E ). Considering variants in high LD (r 2 > 0.9) does not affect this 8 trend ( Figure 4E ). Similarly, after limiting the analysis to the variants with the maximum number of overlaps in each LD 9 block, 24% (64871 / 271732) of the eQTL with enhancer overlap are identified by only one enhancer set ( Figure 4E ).
10
Furthermore, restriction to context-specific eQTL in liver or heart does increase the enrichment for eQTL across most 11 methods, but the distribution of shared eQTL remains similar ( Figure 4E ; Table S8 ). Thus, the interpretation of variants in 12 regions known to influence gene regulation varies substantially depending on the enhancer identification strategy used. identified by both methods for the enhancer sets are relevant to the associated context (Table 2 ). However, most of the 22 associated terms for the target-mapping approach were near the root of the ontologies and thus lacking in functional 23 specificity (Table 2) , likely due to the large gene target lists for most enhancer sets (Table S9) . As a result, we focus on 24 the results from GREAT here, and report the results based on JEME target mapping in Figures S9 and S10.
25
The majority of the top 30 significant annotations from GREAT for each enhancer set are not enriched in any 26 other set in the same context, and no terms are shared by all of the methods in a given context ( Figure 4F , lower triangle).
27
In most of these pairwise comparisons, fewer than half of the GO terms are shared between a pair of enhancer sets. 
41
This suggests different functional influences for enhancer sets from the same context identified by different methods, with
42
FANTOM as a particular outlier. We note that enhancer target gene identification remains a challenging problem, and 43 both strategies for mapping enhancers to potential target genes considered here (GREAT and JEME) likely include false 44 positives. However, insofar as they reflect the regulatory context of the different enhancer sets, they reveal significant 45 functional differences between enhancer identification methods.
47
Genomic and functional clustering of enhancer sets
Our analyses of enhancer sets within the same biological context reveal widespread dissimilarity in both genomic and 1 functional features. To summarize and compare the overall genomic and functional similarity of the enhancer sets across 2 contexts, we clustered them using hierarchical clustering and multidimensional scaling (MDS) based on their Jaccard 3 similarity in genomic space and the GO term functional similarity of predicted target genes (Methods). 
). For example, the ChromHMM set from heart is more similar to other heart enhancer sets than to ChromHMM sets 16 from other contexts. In contrast, the enhancer set similarities in functional space are less conserved by biological context 17 ( Figure 5F ). Here, the heart ChromHMM set is functionally more similar to the H3K27acMinusH3K4me3 set from liver 18 cells than other heart enhancer sets. In general, cell line enhancer sets (red and green) show more functional continuity 19 than heart and liver sets (blue and purple). However, the FANTOM enhancers are exceptions to these trends; FANTOM 20 enhancers from each context form their own cluster based on their genomic distribution, underscoring their uniqueness.
22
Combining enhancer sets does not strongly increase evidence for regulatory function 
33
1.62x for 6). There is a modest increase in the enrichment for overlap with GWAS SNPs among enhancers identified by 34 more identification methods; however, given the relatively small number of GWAS SNP overlaps, none of these 35 differences were statistically significant ( Figure 6B ). We observed no increase in the enrichment for overlap with eQTL as 36 the support for enhancer activity increased ( Figure 6C ). Thus, we do not find strong evidence of increased functional 37 importance in enhancers identified by multiple methods compared to enhancers identified by a single method.
38
Importantly, this implies that intersecting enhancer identification strategies will focus on a smaller set of enhancers with . This provides further evidence that building enhancer sets by simple combinations of existing methods is unlikely to lead to a higher confidence subset, and that filtering based on simple agreement between 1 methods may not improve the specificity of enhancer predictions.
3
A tool for evaluating of the robustness of conclusions across enhancer identification strategies 
34
In this section, we first describe the different enhancer identification strategies that we consider. We then describe how we 35 obtained various annotations of functionally relevant attributes for these enhancers. Finally, we describe the analytical 36 approaches used to compare the enhancer sets to one another in terms of their genomic locations and annotations.
38
Enhancer identification methods
39
Here, we summarize how we defined human enhancer sets across four biological contexts. All analyses were performed in 40 the context of the GRCh37/hg19 build of the human genome. We used TSS definitions from Ensembl v75 (GRCh37.p13).
41
We downloaded broad peak ChIP-seq data for three histone modifications, H3K27ac, H3K4me1, 
38
Experimentally validated enhancer sequences with activity in the heart and all negative enhancer sequences were 39 downloaded from the VISTA enhancer browser (downloaded 11-16-2017) 46 . We also downloaded sequences and Sharpr-
40
MPRA activity levels for 15,720 putative enhancer regions tested for regulatory activity in K562 cells using a massively 41 parallel reporter assay (MPRA) 47 . The Sharpr-MPRA algorithm infers a regulatory score for each base pair in a region 
47
Genomic region overlap and similarity
To quantify genomic similarity, we calculated the base pair overlap between two sets of genomic regions, A and B, by 1 dividing the number of overlapping base pairs in A and B by the total number of base pairs in B. We also performed this 2 calculation on element-wise level, by counting the number of genomic regions in B overlapping regions in A by at least 1 3 bp, and dividing by the number of genomic regions in B. We performed both calculations for each pairwise combination 4 of enhancer sets. All overlaps were computed using programs from the BEDtools v2.23.0 suite 48 .
5
We also evaluated the similarity between pairs of genomic region sets using the Jaccard similarity index. The 6 Jaccard index is defined as the cardinality of the intersection of two sets divided by cardinality of the union. In our 7
analyses, we calculated the Jaccard index at the base pair level. We also computed the relative Jaccard similarity as the 8 observed Jaccard similarity divided by the maximum possible Jaccard similarity for the given sets of genomic regions, 9
i.e., the number of bases in the smaller set divided by the number of bases in the union of the two sets. To visualize 10 overlaps, we plotted heatmaps for pairs of methods using ggplot2 in R 49 .
12
Genomic region overlap enrichment analysis 
25
Enhancer conservation, GWAS catalog SNP, and GTEx eQTL enrichment
26
In addition to comparing the overlap between pairs of enhancer sets, we also computed enrichment for overlap of 27 evolutionarily conserved regions, GWAS SNPs, and GTEx eQTL with each of the enhancer sets. For conserved elements, 28 we proceeded as described above for comparisons between pairs of enhancer sets, but considered the conserved elements 29 as set A and the enhancers as set B. For GWAS tag SNPs, we considered each variant as a region in set A and the enhancer 30 regions as set B. We used the same approach for testing all variants in LD (r 2 > 0.9) with GWAS tag SNPs and for testing 31 enrichment for liver-and heart-specific GWAS tag SNP sets. We also tested for enrichment using only the variant with 32 the maximum number of enhancer set overlaps for each GWAS SNP's LD block. In this analysis, A was the set of variants 33 with maximum enhancer set overlap for each LD block and B was the set of enhancers. Enrichments were computed for 34 the eQTL SNP sets using the same strategy as described for GWAS SNPs.
36
Enhancer set Gene Ontology annotation and similarity
37
We used GREAT to find Gene Ontology (GO) annotations enriched among genes nearby the enhancer sets. GREAT 38 assigns each input region to regulatory domains of genes and uses both a binomial and a hypergeometric test to discover 39 significant associations between regions and associated genes' GO annotation terms 51 . Due to the large number of 40 reported regions in each enhancer set, we considered significance based only on the binomial test with the Bonferroni 41 multiple testing correction (<0.05). We downloaded up to 1,000 significant terms for each enhancer set from the 42 Molecular Function (MF) and Biological Process (BP) GO ontologies. We calculated the similarity between lists of GO 43 terms using the GOSemSim package in R 52 . GOSemSim uses sematic similarity metric that accounts for the hierarchical 44 organization and relatedness of GO terms when calculating the similarity score 53 . For each pair of enhancer sets, we 45 calculated the similarity between their associated GO terms, and converted the resulting similarity matrix into a 46 dissimilarity matrix. We also calculated the number of shared GO terms between pairs of methods and manually compared the top ten significant terms for each enhancer set.
Since enhancers often target genes over long distances, we also considered target predictions generated by the 1 JEME algorithm to assign enhancers to potential target genes in each context 54 . JEME is a two-step process that considers 2 the superset of all enhancers across contexts as well as context-specific biomarkers to make its predictions. By 3 intersecting each enhancer set with the corresponding enhancer-target maps from JEME, we created a set of putatively 4 regulated genes for each method in a given context. We performed GO enrichment analyses on the gene sets using the 5 online tool WebGestalt 55 . We downloaded the top 1,000 significant terms (p < 0.05 after Bonferroni correction) for each 6 enhancer set from the BP and MF GO ontologies, and calculated the pairwise similarity between lists of GO terms using 7 the same semantic similarity metric as above.
9
Genomic and functional clustering of enhancer sets
10
To identify groups of similar enhancers in genomic and functional space, we performed hierarchical clustering on the 11 enhancer sets. For genomic similarity, we converted the pairwise Jaccard similarity to a dissimilarity score by subtracting 12 it from 1 and then clustered the enhancer sets based on these values. For functional similarity, we clustered the lists of 13 GO terms returned by GREAT for each enhancer set. We calculated similarity using the GoSemSim package in R and 14 converted it to dissimilarity by subtracting the similarity score from 1. Supplemental data include seventeen figures (S1-S17) and ten tables (S1-S10).
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5
The fold changes for the primary tissues-liver and heart-are significantly lower than the cell lines-K562 and 6
Gm12878 (p = 4.11E-21 Kruskal-Wallis test, followed by Dunn's test with Bonferroni correction for pairwise 7 comparisons between contexts). The patterns are similar for element-wise comparisons ( Figures S3 and S4 Liver Enhancer Overlap (bp) 
